Riskpilot← Back to searchSign inGet full accessSvea Vaccin AB
ABActiveOrg 5564548849Sveavägen 16General medical practice activities · NACE 8621Est. 1992100-199 employees
Revenue 2024
SEK 131,4M
-35% vs 2023
EBITDA margin
-18.2%
-242% vs 2023
Equity ratio
19.2%
Financial strength
Net profit 2024
SEK -16,9M
-264% vs 2023
| Revenue | SEK 131,4M | -35% |
| EBITDA | SEK -23,9M | -242% |
| Net profit | SEK -16,9M | -264% |
| Total assets | SEK 22,9M | -51% |
| Equity | SEK 4,4M | -61% |
| Employees | — | — |
Legal name
Svea Vaccin AB
Org number
5564548849
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
21 oktober 1992
Share capital
SEK 100 000
Employees
100-199
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva läkarpraktik med inriktning mot vaccinationer samt äga och förvalta värdepapper.
Address
Sveavägen 16
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 109 039 | 233 868 | 169 152 | 200 780 | 131 384 |
| Staff expenses | — | — | −51 979 | — | — |
| EBITDA | 5 932 | 52 110 | 18 033 | 16 789 | −23 873 |
| Depreciation & amort. | −400 | −233 | −157 | −383 | −922 |
| EBIT | 5 532 | 51 877 | 17 876 | 16 406 | −24 795 |
| Net financials | −20 | −41 | 4 | 151 | −111 |
| Profit before tax | 5 513 | 51 836 | 14 250 | 13 056 | −16 906 |
| Tax | −1 201 | −10 710 | −2 808 | −2 750 | −0 |
| Net profit | 4 312 | 41 126 | 11 442 | 10 306 | −16 906 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 30 483 | 66 383 | 37 262 | 46 228 | 22 857 |
| Equity | 4 432 | 41 557 | 11 999 | 11 305 | 4 399 |
| Long-term debt | 0 | 0 | — | 0 | 0 |
| Short-term debt | 26 052 | 24 825 | 20 763 | 26 923 | 18 458 |
| Total debt | 26 052 | 24 825 | 20 763 | 26 923 | 18 458 |
EBITDA margin
-18.2%
This company
15.8%
Market median
-215% vs market
20202024
Equity ratio
19.2%
This company
38.2%
Market median
-50% vs market
20202024
Return on equity
-384.3%
This company
18.4%
Market median
-2189% vs market
20202024
Net profit margin
-12.9%
This company
8.1%
Market median
-259% vs market
20202024
Asset turnover
5.75×
This company
1.12×
Market median
+413% vs market
20202024
Debt / equity
4.20×
This company
0.62×
Market median
-577% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SJ Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
BH Chief Auditor | Chief Auditor | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Svea Vaccin Holding AB
Svea Vaccin AB Board members of Svea Vaccin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Henrik Johansson | Chief Auditor | 0 companies |
| Sebastian Johan Lennevi | Chief Auditor | 0 companies |
| Mayah Satarvandi | Deputy Board Member | 0 companies |
| Sana Bent Salem Hadfi | Deputy Board Member | 0 companies |
| Mohamed Ridha Ben Ahmed Hadfi | Board of Directors | 0 companies |